Bright Minds Biosciences (DRUG): Net earnings per share for the last 12 months

Bright Minds Biosciences (DRUG) is developing a biopharmaceutical cluster of targeted therapies to combat depression and CNS pathologies. Earnings per share over the last four quarters demonstrate financial dynamics where -2.08 expresses the current value of the metric. Management is focused on creating safe serotonin-based drugs for epilepsy. High long-term market potential is driven by demand for medications without hallucinogenic effects.
Analytical breakdowns and data insights for company Bright Minds Biosciences Inc (DRUG)

For Bright Minds Biosciences (DRUG), whose market capitalization depends on the success of psychedelic clinical trials, this indicator serves as a measure of effectiveness in overcoming a financial crisis. By analyzing the 12-month net income per share snapshot on the GURU.Markets platform, an investor sees the result of dividing total net income by the number of shares, which allows for an assessment of the business's real value and prevents overpaying for the asset.